Jul 16, 2021

Plasma Dilution Potential Benefits & Real Cases Part III | Dr Dobri Kiprov Interview Series

Posted by in categories: biotech/medical, life extension, neuroscience

Interested in living longer? You are probably going to get TPE at some point. The Conboys are looking for funding for human trials to produce a product in 3–4 years. Here we have infor on what it is and how it works plus actual human results to date (starting at 10 minutes).

In Part III, Dr Kiprov, discusses the history of moving from the Conboy’s experiments in the lab to the process used in the clinic and reasons for the choices made. He also covers the benefits that he has seen with plasma exchange in the clinic.

Part I Video Link
Part II Video Link

Dr Dobri Kiprov is internationally recognized as a pioneer and a leading expert in the field of Therapeutic Apheresis. He is Chief of the Division of Immunotherapy at California Pacific Medical Center in San Francisco, California and Medical Director of Apheresis Care Group (ACG).

Dr Kiprov has been working with the Drs Conboy for many years on plasma exchange and recently they published a joint paper based on their experience in the clinic and the laboratory.

Dobri Kiprov, M.D., H.P. (ASCP) — Home page.

Some examples papers from Dr Kiprov.
Therapeutic plasma exchange (TPE) and blood products — Implications for longevity and disease.
Attenuation of age-elevated blood factors by repositioning plasmapheresis: A novel perspective and approach.
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study.

Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.

Comments are closed.